Breast Cancer Research
Puma Biotechnology Inc. focuses on clinical research in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer, with interest in treatment settings where disease has returned or spread.
- Metastatic breast cancer
- Hormone receptor-positive disease
- HER2-negative breast cancer
The sponsor’s research activity is centered on therapies used alongside endocrine therapy in advanced breast cancer care.
Endocrine Therapy Combinations
Clinical interest extends to combining investigational oncology agents with hormone therapy for patients with HR+ breast cancer, reflecting a therapeutic focus on endocrine-sensitive disease.
- Hormone therapy combinations
- Endocrine-sensitive breast cancer
- Combination oncology treatment
Research is directed toward treatment strategies intended for patients whose tumors remain responsive to hormonal manipulation.
Oncology Drug Development
The sponsor’s clinical portfolio includes evaluation of alisertib in breast cancer, highlighting an interest in targeted oncology agents for difficult-to-treat advanced disease.
- Targeted cancer therapeutics
- Advanced breast cancer
- Investigational oncology agents
This area reflects a focus on therapies intended to address unmet needs in metastatic oncology.
Metastatic Disease Management
Research activity is concentrated in the setting of recurrent and metastatic breast cancer, where treatment selection is shaped by disease spread and prior therapy exposure.
- Recurrent cancer
- Metastatic disease
- Breast cancer treatment
The clinical emphasis is on patients with advanced disease requiring systemic treatment options.
